董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Lance A. Berry | 男 | Independent Director | 52 | 未披露 | 未持股 | 2025-11-05 |
| Elizabeth S. Hanna | 女 | Independent Director | 60 | 未披露 | 未持股 | 2025-11-05 |
| Deepti Jain | 女 | Independent Director | 57 | 未披露 | 未持股 | 2025-11-05 |
| Jane E. Kiernan | 女 | Independent Director | 64 | 未披露 | 未持股 | 2025-11-05 |
| Lawrence W. Hamilton | 男 | Independent Director | 67 | 17.50万美元 | 未持股 | 2025-11-05 |
| John T. Treace | 男 | Chief Executive Officer, Chairman of the Board and Founder | 53 | 37.09万美元 | 未持股 | 2025-11-05 |
| John Bakewell | 男 | Independent Director | 64 | 17.50万美元 | 未持股 | 2025-11-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mark L. Hair | 男 | Chief Financial Officer | 55 | 92.44万美元 | 未持股 | 2025-11-05 |
| Sean F. Scanlan | 男 | Chief Innovation Officer | 43 | 未披露 | 未持股 | 2025-11-05 |
| Scot M. Elder | 男 | Chief Legal and Compliance Officer and Corporate Secretary | 50 | 未披露 | 未持股 | 2025-11-05 |
| Gaetano M. Guglielmino | 男 | Chief Commercial Officer | 55 | 未披露 | 未持股 | 2025-11-05 |
| Aaron J. Berutti | 男 | Senior Vice President, Sales | 46 | 未披露 | 未持股 | 2025-11-05 |
| John T. Treace | 男 | Chief Executive Officer, Chairman of the Board and Founder | 53 | 37.09万美元 | 未持股 | 2025-11-05 |
董事简历
中英对照 | 中文 | 英文- Lance A. Berry
-
Lance A. Berry ，2015年10月被任命为Tornier N.V.高级副总裁和财务总监，在Wright/Tornier合并之时。2009年起，担任Wright Medical Group, Inc.的高级副总裁和财务总监。2002年加入legacy Wright，一直到任命财务总监，担任副总裁和企业总会计师。此前，1995-2002年，他担任Arthur Andersen LLP的Tennessee州Memphis港 办事处担任审计经理。他是一名注册会计师，非执业。
Lance A. Berry,has served as the Company's Chief Financial Officer and Treasurer since his appointment on December 4, 2023. Prior to joining the Company, Mr. Berry most recently served from January 2019 until November 2020 as the Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V. ("Wright"), until it was acquired by Stryker in November 2020. Previously, Mr. Berry served as the Senior Vice President, Chief Financial Officer for Wright from 2009 to 2018 and as its Vice President, Corporate Controller from 2002 to 2009. Before joining Wright in 2002, Mr. Berry served as a certified public accountant for Arthur Andersen. Mr. Berry currently serves on the board of directors of a public company, Treace Medical Concepts, Inc. Mr. Berry earned bachelor's and master's degrees in accounting from the University of Mississippi in 1994 and 1995, respectively. - Lance A. Berry ，2015年10月被任命为Tornier N.V.高级副总裁和财务总监，在Wright/Tornier合并之时。2009年起，担任Wright Medical Group, Inc.的高级副总裁和财务总监。2002年加入legacy Wright，一直到任命财务总监，担任副总裁和企业总会计师。此前，1995-2002年，他担任Arthur Andersen LLP的Tennessee州Memphis港 办事处担任审计经理。他是一名注册会计师，非执业。
- Lance A. Berry,has served as the Company's Chief Financial Officer and Treasurer since his appointment on December 4, 2023. Prior to joining the Company, Mr. Berry most recently served from January 2019 until November 2020 as the Executive Vice President, Chief Financial and Operations Officer of Wright Medical Group N.V. ("Wright"), until it was acquired by Stryker in November 2020. Previously, Mr. Berry served as the Senior Vice President, Chief Financial Officer for Wright from 2009 to 2018 and as its Vice President, Corporate Controller from 2002 to 2009. Before joining Wright in 2002, Mr. Berry served as a certified public accountant for Arthur Andersen. Mr. Berry currently serves on the board of directors of a public company, Treace Medical Concepts, Inc. Mr. Berry earned bachelor's and master's degrees in accounting from the University of Mississippi in 1994 and 1995, respectively.
- Elizabeth S. Hanna
-
Elizabeth S. Hanna被任命为Cyted Health，Inc.的总裁，该公司是一家为食道疾病提供基因组诊断测试的供应商。2022年3月至2023年9月，Hanna女士担任分子诊断测试解决方案提供商Agendia，Inc.的执行副总裁兼首席商务官。她曾于2019年1月至2022年3月担任癌症诊断解决方案提供商Clinical Genomics，Inc.的总裁兼首席执行官和董事会成员。从2018年10月直至晋升，她担任临床基因组学首席商务官。2014年12月至2018年9月，她担任临床阶段生物技术公司Origin，Inc.的总裁兼首席运营官。从2006年到2014年4月，Hanna女士在强生（NYSE：JNJ）担任越来越重要的职务，包括最近在2012年10月至2014年4月担任全球战略营销– Acuvue品牌副总裁。她还曾于2012年10月至2014年4月担任强生视力保健全球管理委员会成员。Hanna女士拥有伊利诺伊大学化学工程学士学位和哈佛商学院MBA学位。
Elizabeth S. Hanna,was appointed President of Cyted Health, Inc., a provider of genomic diagnostic tests for diseases of the esophagus. From March 2022 to September 2023, Ms. Hanna served as Executive Vice President and Chief Commercial Officer of Agendia, Inc., a provider of molecular diagnostic test solutions. She served as President and Chief Executive Officer and a board member of Clinical Genomics, Inc., a provider of cancer diagnostic solutions, from January 2019 to March 2022. From October 2018 until her promotion, she was Chief Commercial Officer of Clinical Genomics. From December 2014 to September 2018, she served as President and Chief Operating Officer of Origin, Inc., a clinical-stage biotech company. From 2006 to April 2014, Ms. Hanna held positions of increasing responsibility at Johnson & Johnson (NYSE: JNJ), including most recently as Vice President, Global Strategic Marketing – Acuvue Brand from October 2012 to April 2014. She also served as a member of the Global Management Board for J&J Vision Care from October 2012 to April 2014. Ms. Hanna holds a BS in Chemical Engineering from the University of Illinois and an MBA from Harvard Business School. - Elizabeth S. Hanna被任命为Cyted Health，Inc.的总裁，该公司是一家为食道疾病提供基因组诊断测试的供应商。2022年3月至2023年9月，Hanna女士担任分子诊断测试解决方案提供商Agendia，Inc.的执行副总裁兼首席商务官。她曾于2019年1月至2022年3月担任癌症诊断解决方案提供商Clinical Genomics，Inc.的总裁兼首席执行官和董事会成员。从2018年10月直至晋升，她担任临床基因组学首席商务官。2014年12月至2018年9月，她担任临床阶段生物技术公司Origin，Inc.的总裁兼首席运营官。从2006年到2014年4月，Hanna女士在强生（NYSE：JNJ）担任越来越重要的职务，包括最近在2012年10月至2014年4月担任全球战略营销– Acuvue品牌副总裁。她还曾于2012年10月至2014年4月担任强生视力保健全球管理委员会成员。Hanna女士拥有伊利诺伊大学化学工程学士学位和哈佛商学院MBA学位。
- Elizabeth S. Hanna,was appointed President of Cyted Health, Inc., a provider of genomic diagnostic tests for diseases of the esophagus. From March 2022 to September 2023, Ms. Hanna served as Executive Vice President and Chief Commercial Officer of Agendia, Inc., a provider of molecular diagnostic test solutions. She served as President and Chief Executive Officer and a board member of Clinical Genomics, Inc., a provider of cancer diagnostic solutions, from January 2019 to March 2022. From October 2018 until her promotion, she was Chief Commercial Officer of Clinical Genomics. From December 2014 to September 2018, she served as President and Chief Operating Officer of Origin, Inc., a clinical-stage biotech company. From 2006 to April 2014, Ms. Hanna held positions of increasing responsibility at Johnson & Johnson (NYSE: JNJ), including most recently as Vice President, Global Strategic Marketing – Acuvue Brand from October 2012 to April 2014. She also served as a member of the Global Management Board for J&J Vision Care from October 2012 to April 2014. Ms. Hanna holds a BS in Chemical Engineering from the University of Illinois and an MBA from Harvard Business School.
- Deepti Jain
-
Deepti Jain，曾担任IngenioRx，Inc.的总裁，该公司是Anthem, Inc.（NYSE：ANTM）的子公司。2014年至2018年，Jain女士担任Anthem, Inc.旗下部门Anthem Pharmacy Solutions的高级副总裁兼首席运营官。Jain女士于2010年至2012年担任Medco Health Solutions Inc.健康计划部门的首席财务官和财务高级副总裁。Jain女士于2021年1月至2023年5月期间担任医疗器械上市公司Tactile Systems Technology, Inc.（纳斯达克股票代码：TCMD）的董事会、审计委员会以及合规和报销委员会成员。Jain女士拥有Dayanand Anglo Vedic学院的哲学和古典音乐学士学位、Guru Nanak Dev大学的英国文学硕士学位和巴鲁克学院Zicklin商学院的MBA学位。
Deepti Jain,served as the President of IngenioRx, Inc., a subsidiary of Anthem, Inc. (NYSE: ANTM). From 2014 to 2018, Ms. Jain served as Senior Vice President and Chief Operating Officer of Anthem Pharmacy Solutions, a division of Anthem, Inc. Ms. Jain served as Chief Financial Officer and Senior Vice President of Finance of the Health Plan Division of Medco Health Solutions Inc. from 2010 to 2012. Ms. Jain served as a member of the board of directors, audit committee and compliance and reimbursement committee of Tactile Systems Technology, Inc. (NASDAQ: TCMD), a publicly traded medical device company, from January 2021 to May 2023. Ms. Jain holds a BA in Philosophy and Classical Music from Dayanand Anglo Vedic College, an MA in English Literature from Guru Nanak Dev University and an MBA from Zicklin School of Business at Baruch College. - Deepti Jain，曾担任IngenioRx，Inc.的总裁，该公司是Anthem, Inc.（NYSE：ANTM）的子公司。2014年至2018年，Jain女士担任Anthem, Inc.旗下部门Anthem Pharmacy Solutions的高级副总裁兼首席运营官。Jain女士于2010年至2012年担任Medco Health Solutions Inc.健康计划部门的首席财务官和财务高级副总裁。Jain女士于2021年1月至2023年5月期间担任医疗器械上市公司Tactile Systems Technology, Inc.（纳斯达克股票代码：TCMD）的董事会、审计委员会以及合规和报销委员会成员。Jain女士拥有Dayanand Anglo Vedic学院的哲学和古典音乐学士学位、Guru Nanak Dev大学的英国文学硕士学位和巴鲁克学院Zicklin商学院的MBA学位。
- Deepti Jain,served as the President of IngenioRx, Inc., a subsidiary of Anthem, Inc. (NYSE: ANTM). From 2014 to 2018, Ms. Jain served as Senior Vice President and Chief Operating Officer of Anthem Pharmacy Solutions, a division of Anthem, Inc. Ms. Jain served as Chief Financial Officer and Senior Vice President of Finance of the Health Plan Division of Medco Health Solutions Inc. from 2010 to 2012. Ms. Jain served as a member of the board of directors, audit committee and compliance and reimbursement committee of Tactile Systems Technology, Inc. (NASDAQ: TCMD), a publicly traded medical device company, from January 2021 to May 2023. Ms. Jain holds a BA in Philosophy and Classical Music from Dayanand Anglo Vedic College, an MA in English Literature from Guru Nanak Dev University and an MBA from Zicklin School of Business at Baruch College.
- Jane E. Kiernan
-
Jane E. Kiernan，她一直担任Salter Labs的首席执行官（2010年以来）。从2007年到2010年，她曾担任Baxter Healthcare Corporation（上市公司Baxter International公司的首席运营子公司）的勃脉力总经理。从2003年到2007年3月，她曾担任Baxter Nutrition（Baxter Healthcare Corporation的一个部门，肠外营养产品的供应商）的总经理。从2001年到2003年，她曾担任Specialty Therapies公司（Baxter Healthcare Corporation的其它部门）的总经理。从2000年到2001年，她曾担任Baxter Healthcare Corporation的战略副总裁。从1995年到2000年，她曾担任Allegiance Healthcare Corporation（医疗产品和服务的供应商）的负责财务、分销和服务的副总裁。
Jane E. Kiernan has served as Chair of our compensation committee since December 2020 and a member of the Board, a member of our audit committee, and a member of our compensation committee since April 2019. Ms. Kiernan has over 30 years of executive and management leadership in health care with both public and private companies. Ms. Kiernan is a co-founder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, health care corporations and philanthropic health care foundation partners. From 2010 to 2017 Ms. Kiernan served as the Chief Executive Officer of Salter Labs, a manufacturer of specialty medical devices. From 2006 to 2011 Ms. Kiernan served on the board of directors and as Chair of the audit committee of American Medical Systems Holdings Inc. prior to it being acquired by Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., a subsidiary of Endo International plc. From 2001 to 2010 Ms. Kiernan held executive and general management positions with Baxter Healthcare Corporation. Prior to 2001 she held corporate and line management roles in finance, strategy, marketing, and operations with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Ms. Kiernan serves on the board of directors of Ryan Banks Academy, an urban boarding school in Chicago, and has served as committee Chair and on the board of directors of the American Red Cross of Greater Chicago. In addition, she is a past president of the Healthcare Businesswomen's Association, Chicago Chapter. Ms. Kiernan holds a B.S. in business from Southern Methodist University. - Jane E. Kiernan，她一直担任Salter Labs的首席执行官（2010年以来）。从2007年到2010年，她曾担任Baxter Healthcare Corporation（上市公司Baxter International公司的首席运营子公司）的勃脉力总经理。从2003年到2007年3月，她曾担任Baxter Nutrition（Baxter Healthcare Corporation的一个部门，肠外营养产品的供应商）的总经理。从2001年到2003年，她曾担任Specialty Therapies公司（Baxter Healthcare Corporation的其它部门）的总经理。从2000年到2001年，她曾担任Baxter Healthcare Corporation的战略副总裁。从1995年到2000年，她曾担任Allegiance Healthcare Corporation（医疗产品和服务的供应商）的负责财务、分销和服务的副总裁。
- Jane E. Kiernan has served as Chair of our compensation committee since December 2020 and a member of the Board, a member of our audit committee, and a member of our compensation committee since April 2019. Ms. Kiernan has over 30 years of executive and management leadership in health care with both public and private companies. Ms. Kiernan is a co-founder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, health care corporations and philanthropic health care foundation partners. From 2010 to 2017 Ms. Kiernan served as the Chief Executive Officer of Salter Labs, a manufacturer of specialty medical devices. From 2006 to 2011 Ms. Kiernan served on the board of directors and as Chair of the audit committee of American Medical Systems Holdings Inc. prior to it being acquired by Endo Health Solutions Inc., formerly Endo Pharmaceuticals Holdings Inc., a subsidiary of Endo International plc. From 2001 to 2010 Ms. Kiernan held executive and general management positions with Baxter Healthcare Corporation. Prior to 2001 she held corporate and line management roles in finance, strategy, marketing, and operations with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Ms. Kiernan serves on the board of directors of Ryan Banks Academy, an urban boarding school in Chicago, and has served as committee Chair and on the board of directors of the American Red Cross of Greater Chicago. In addition, she is a past president of the Healthcare Businesswomen's Association, Chicago Chapter. Ms. Kiernan holds a B.S. in business from Southern Methodist University.
- Lawrence W. Hamilton
-
Lawrence W. Hamilton，从1996年到2006年在 Tech Data Corporation担任高级副总裁，人力资源总监，是一家信息技术公司的分销商。他从1993年到1996年担任副总裁，人力资源总监。从1985年到1993年，Hamilton先生曾在Bristol-Myers Squibb Company担任各种人力资源管理职务，包括从1991年到1993年在Linvatec Corp.担任副总裁、人力资源和管理总监，这是Bristol-Myers Squibb Company的一个关节镜和内窥镜部门。Hamilton先生在人力资源方面是一个认证的高级专业人士，并且在最近收到了从美国薪酬协会（the American Compensation Association。）的认证补偿专业名称。
Lawrence W. Hamilton,has served as an Executive Coach and Senior Adjunct Faculty with the Leadership Development Institute at Eckerd College since September 2008. From July 1993 to July 2006, Mr. Hamilton served in various roles at Tech Data Corporation, most recently as Senior Vice President, Human Resources and Chief Human Resources Officer. From 1991 to 1993, Mr. Hamilton served as Vice President of Human Resources and Administration at Linvatec. From 1985 to 1991, Mr. Hamilton served in a variety of human resource management positions at Bristol-Myers Squibb Company (NYSE: BMY). Mr. Hamilton has also previously served as a member of the board of directors of Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, and HomeBanc Mortgage (NYSE: HBMC). Mr. Hamilton holds a BA in Political Sciences from Fisk University, an MPA (Labor) Policy from the University of Alabama and an Ed.S. in Human Resources Development from George Washington University. Mr. Hamilton is a certified Senior Professional in Human Resources and holds the Certified Compensation Professional designation from the American Compensation Association and the Board Certified Coach credential from the Center For Credentialing and Education. - Lawrence W. Hamilton，从1996年到2006年在 Tech Data Corporation担任高级副总裁，人力资源总监，是一家信息技术公司的分销商。他从1993年到1996年担任副总裁，人力资源总监。从1985年到1993年，Hamilton先生曾在Bristol-Myers Squibb Company担任各种人力资源管理职务，包括从1991年到1993年在Linvatec Corp.担任副总裁、人力资源和管理总监，这是Bristol-Myers Squibb Company的一个关节镜和内窥镜部门。Hamilton先生在人力资源方面是一个认证的高级专业人士，并且在最近收到了从美国薪酬协会（the American Compensation Association。）的认证补偿专业名称。
- Lawrence W. Hamilton,has served as an Executive Coach and Senior Adjunct Faculty with the Leadership Development Institute at Eckerd College since September 2008. From July 1993 to July 2006, Mr. Hamilton served in various roles at Tech Data Corporation, most recently as Senior Vice President, Human Resources and Chief Human Resources Officer. From 1991 to 1993, Mr. Hamilton served as Vice President of Human Resources and Administration at Linvatec. From 1985 to 1991, Mr. Hamilton served in a variety of human resource management positions at Bristol-Myers Squibb Company (NYSE: BMY). Mr. Hamilton has also previously served as a member of the board of directors of Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, and HomeBanc Mortgage (NYSE: HBMC). Mr. Hamilton holds a BA in Political Sciences from Fisk University, an MPA (Labor) Policy from the University of Alabama and an Ed.S. in Human Resources Development from George Washington University. Mr. Hamilton is a certified Senior Professional in Human Resources and holds the Certified Compensation Professional designation from the American Compensation Association and the Board Certified Coach credential from the Center For Credentialing and Education.
- John T. Treace
-
John T. Treace，于2014年创立Treace Medical Concepts，并担任Treace Medical Concepts， Inc.的董事。Treace Medical Concepts, Inc.的首席执行官和成员。自Treace Medical Concepts， Inc.成立以来担任董事会成员。在此之前，Treace先生于2010年1月至2013年1月担任美国销售和全球营销高级副总裁，2003年1月至2009年12月担任生物制剂和四肢副总裁，2001年7月至2003年6月担任生物制剂营销高级总监，2000年11月至2001年6月担任Wright Medical Group， Inc.（一家医疗器械公司，于2020年11月被Stryker Corporation（纽约证券交易所股票：SYK）收购）的销售行政高级总监。在此之前，他曾担任Xomed Surgical Products， Inc.的职位，包括从1998年6月到2000年9月担任营销总监，从1996年4月到1998年6月担任高级产品经理。从2010年7月到2013年7月，Treace先生担任ENTrigue Surgical（被Arthrocare Corporation收购）的董事会成员。他持有Seattle大学的金融学士学位。
John T. Treace,founded Treace Medical Concepts in 2014 and has served as Treace Medical Concepts, Inc. Chief Executive Officer and a member of Treace Medical Concepts, Inc. Board since Treace Medical Concepts, Inc. inception. Before that, Mr. Treace served as Senior Vice President of U.S. Sales and Global Marketing from January 2010 to January 2013, as Vice President, Biologics and Extremities, from January 2003 to December 2009, as Senior Director of Biologics Marketing from July 2001 to June 2003, and as Senior Director of Sales Administration from November 2000 to June 2001 for Wright Medical Group, Inc., a medical device company, which was acquired by Stryker Corporation (NYSE: SYK) in November 2020. Before that, Mr. Treace held positions at Xomed Surgical Products, Inc., including as Director of Marketing from June 1998 to September 2000 and as Senior Product Manager from April 1996 to June 1998. From July 2010 to July 2013, Mr. Treace served on the board of directors of ENTrigue Surgical, which was acquired by Arthrocare Corporation. Mr. Treace holds a BS in Finance from Seattle University. - John T. Treace，于2014年创立Treace Medical Concepts，并担任Treace Medical Concepts， Inc.的董事。Treace Medical Concepts, Inc.的首席执行官和成员。自Treace Medical Concepts， Inc.成立以来担任董事会成员。在此之前，Treace先生于2010年1月至2013年1月担任美国销售和全球营销高级副总裁，2003年1月至2009年12月担任生物制剂和四肢副总裁，2001年7月至2003年6月担任生物制剂营销高级总监，2000年11月至2001年6月担任Wright Medical Group， Inc.（一家医疗器械公司，于2020年11月被Stryker Corporation（纽约证券交易所股票：SYK）收购）的销售行政高级总监。在此之前，他曾担任Xomed Surgical Products， Inc.的职位，包括从1998年6月到2000年9月担任营销总监，从1996年4月到1998年6月担任高级产品经理。从2010年7月到2013年7月，Treace先生担任ENTrigue Surgical（被Arthrocare Corporation收购）的董事会成员。他持有Seattle大学的金融学士学位。
- John T. Treace,founded Treace Medical Concepts in 2014 and has served as Treace Medical Concepts, Inc. Chief Executive Officer and a member of Treace Medical Concepts, Inc. Board since Treace Medical Concepts, Inc. inception. Before that, Mr. Treace served as Senior Vice President of U.S. Sales and Global Marketing from January 2010 to January 2013, as Vice President, Biologics and Extremities, from January 2003 to December 2009, as Senior Director of Biologics Marketing from July 2001 to June 2003, and as Senior Director of Sales Administration from November 2000 to June 2001 for Wright Medical Group, Inc., a medical device company, which was acquired by Stryker Corporation (NYSE: SYK) in November 2020. Before that, Mr. Treace held positions at Xomed Surgical Products, Inc., including as Director of Marketing from June 1998 to September 2000 and as Senior Product Manager from April 1996 to June 1998. From July 2010 to July 2013, Mr. Treace served on the board of directors of ENTrigue Surgical, which was acquired by Arthrocare Corporation. Mr. Treace holds a BS in Finance from Seattle University.
- John Bakewell
-
John Bakewell，2014年6月，他加入Lantheus担任公司首席财务官。2013年6月至2014年5月，他曾担任Interline Brands, Inc., or Interline的首席财务官。加入Interline之前，2010年1月至2011年12月，他担任RegionalCare Hospital Partners的执行副总裁和首席财务官。此外，2000至2009年，他在全球整形外科医疗设备制造商Wright Medical Group担任相同职位。1998至2000年，他担任Altra Energy Technologies的首席财务官；1993至1998年担任Cyberonics, Inc.的首席财务官；1990至1993年担任Zeos International的首席财务官。他还是Keystone Dental, Inc.的董事会成员。他在Northern Iowa大学获得会计学学士学位，是明尼苏达州和爱荷华州的执业注册会计师。
John Bakewell has served as a member of board of directors since November 2020. Before that, from January 2016 to November 2016 Mr. Bakewell served as the Chief Financial Officer of Exact Sciences Corporation NASDAQ: EXAS, a molecular diagnostics company. Before that, from June 2014 to December 2015 he served as Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ: LNTH), a diagnostic medical imaging company. Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020 Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NASDAQ: STIM), a medical technology company, since May 2020 and Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a medical device company, since February 2018. Mr. Bakewell also previously served as a member of the board of directors of Entellus Medical, Inc., now part of Stryker Corporation (NYSE: SYK), ev3 Inc., now part of Medtronic plc (NYSE: MDT) and Corindus Vascular Robotics, Inc., now a Siemens Healthineers company. Mr. Bakewell holds a BA in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive). - John Bakewell，2014年6月，他加入Lantheus担任公司首席财务官。2013年6月至2014年5月，他曾担任Interline Brands, Inc., or Interline的首席财务官。加入Interline之前，2010年1月至2011年12月，他担任RegionalCare Hospital Partners的执行副总裁和首席财务官。此外，2000至2009年，他在全球整形外科医疗设备制造商Wright Medical Group担任相同职位。1998至2000年，他担任Altra Energy Technologies的首席财务官；1993至1998年担任Cyberonics, Inc.的首席财务官；1990至1993年担任Zeos International的首席财务官。他还是Keystone Dental, Inc.的董事会成员。他在Northern Iowa大学获得会计学学士学位，是明尼苏达州和爱荷华州的执业注册会计师。
- John Bakewell has served as a member of board of directors since November 2020. Before that, from January 2016 to November 2016 Mr. Bakewell served as the Chief Financial Officer of Exact Sciences Corporation NASDAQ: EXAS, a molecular diagnostics company. Before that, from June 2014 to December 2015 he served as Chief Financial Officer of Lantheus Holdings, Inc. (NASDAQ: LNTH), a diagnostic medical imaging company. Mr. Bakewell has also previously served at Interline Brands, Inc., RegionalCare Hospital Partners, Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020 Cyberonics, Inc., now part of LivaNova PLC (NASDAQ:LIVN), Altra Energy Technologies, Inc. and ZEOS International, Ltd. Mr. Bakewell has served as a member of the board of directors of Neuronetics, Inc. (NASDAQ: STIM), a medical technology company, since May 2020 and Xtant Medical Holdings, Inc. (NYSE MKT: XTNT), a medical device company, since February 2018. Mr. Bakewell also previously served as a member of the board of directors of Entellus Medical, Inc., now part of Stryker Corporation (NYSE: SYK), ev3 Inc., now part of Medtronic plc (NYSE: MDT) and Corindus Vascular Robotics, Inc., now a Siemens Healthineers company. Mr. Bakewell holds a BA in Accounting from the University of Northern Iowa and is a certified public accountant (current status inactive).
高管简历
中英对照 | 中文 | 英文- Mark L. Hair
Mark L.Hair自2020年9月起担任我们的首席财务官。在此之前，Hair先生于2018年1月至2020年2月担任医疗设备公司Restoration Robotics，Inc.的首席财务官。2016年5月至2017年8月，Hair先生曾担任医疗器械公司ZELTIQAesthetics，Inc.的Vice President兼首席会计官，包括2017年4月被Allergan plc收购。在此之前，Hair先生于2014年9月至2016年1月担任医疗器械公司Thoratec Corporation的Vice President兼公司财务总监，包括2015年10月被St.Jude Medical收购。Hair先生还在DiamondFoods，Inc.公司担任过高级副总裁，财务和公司财务总监，并在Stoneturn Group，LLP和Deloitte，LLP担任过职务。Hair先生拥有杨百翰大学（Brigham Young University）会计学学士学位和会计学硕士学位。
Mark L. Hair,served as the Chief Financial Officer of Restoration Robotics, Inc., a medical device company. From May 2016 to August 2017, Mr. Hair served as the Vice President and Chief Accounting Officer of Zeltiq Aesthetics, Inc., a medical device company, including through its acquisition by Allergan plc in April 2017. From September 2014 to January 2016, Mr. Hair served as the Vice President and Corporate Controller of Thoratec Corporation, a medical device company, including through its acquisition by St. Jude Medical in October 2015. Mr. Hair has also served as Senior Vice President, Finance and Corporate Controller at Diamond Foods, Inc., and also held positions at StoneTurn Group, LLP, and Deloitte, LLP. Mr. Hair holds a BS in Accounting and a Masters of Accountancy from Brigham Young University.- Mark L.Hair自2020年9月起担任我们的首席财务官。在此之前，Hair先生于2018年1月至2020年2月担任医疗设备公司Restoration Robotics，Inc.的首席财务官。2016年5月至2017年8月，Hair先生曾担任医疗器械公司ZELTIQAesthetics，Inc.的Vice President兼首席会计官，包括2017年4月被Allergan plc收购。在此之前，Hair先生于2014年9月至2016年1月担任医疗器械公司Thoratec Corporation的Vice President兼公司财务总监，包括2015年10月被St.Jude Medical收购。Hair先生还在DiamondFoods，Inc.公司担任过高级副总裁，财务和公司财务总监，并在Stoneturn Group，LLP和Deloitte，LLP担任过职务。Hair先生拥有杨百翰大学（Brigham Young University）会计学学士学位和会计学硕士学位。
- Mark L. Hair,served as the Chief Financial Officer of Restoration Robotics, Inc., a medical device company. From May 2016 to August 2017, Mr. Hair served as the Vice President and Chief Accounting Officer of Zeltiq Aesthetics, Inc., a medical device company, including through its acquisition by Allergan plc in April 2017. From September 2014 to January 2016, Mr. Hair served as the Vice President and Corporate Controller of Thoratec Corporation, a medical device company, including through its acquisition by St. Jude Medical in October 2015. Mr. Hair has also served as Senior Vice President, Finance and Corporate Controller at Diamond Foods, Inc., and also held positions at StoneTurn Group, LLP, and Deloitte, LLP. Mr. Hair holds a BS in Accounting and a Masters of Accountancy from Brigham Young University.
- Sean F. Scanlan
Sean F.Scanlan自2021年3月起担任我们的高级副总裁，营销和医学教育，在此之前，自2018年1月起担任我们的Vice President，营销和医学教育，自2014年12月起担任越来越重要的各种营销职务。在此之前，从2011年6月到2014年4月，Scanlan博士担任Smith&Nephew NYSE:SNN的高级外科设备产品开发工程师，专注于产品开发和早期技术评估。在此之前，Scanlan博士从2006年1月到2011年5月领导斯坦福大学（Stanford University）的跨学科临床研究研究，专注于骨科手术和工程，并从2009年10月到2011年5月担任Moximed Inc.的顾问，这是一家早期骨科初创公司。Scanlan先生拥有佛罗里达大学（University of Florida）工程科学（生物力学）学士学位和斯坦福大学（Stanford University）机械工程（生物力学工程系）硕士和博士学位。
Sean F. Scanlan,has served as Treace Medical Concepts, Inc. Chief Innovation Officer since January 2023. From September 2021 until January 2023, he served as Treace Medical Concepts, Inc. Senior Vice President, Marketing, and from March 2021 to September 2021, he served as Treace Medical Concepts, Inc. Senior Vice President, Marketing & Medical Education. From January 2018 to March 2021, Dr. Scanlan served as Treace Medical Concepts, Inc. Vice President, Marketing & Medical Education, after serving in various marketing roles of increasing responsibility since December 2014. From June 2011 to April 2014, Dr. Scanlan served as Product Development Engineer Advanced Surgical Devices at Smith & Nephew (NYSE: SNN), focusing on product development and early-stage technology assessment. From January 2006 to May 2011, Dr. Scanlan led an interdisciplinary clinical research study at Stanford University, focusing on orthopaedic surgery and engineering and, from October 2009 to May 2011, served as a consultant for Moximed Inc., an early-stage orthopaedics start-up company. Dr. Scanlan holds a BS in Engineering Science (Biomechanics) from the University of Florida and an MS and PhD in Mechanical Engineering (Biomechanical Engineering division) from Stanford University.- Sean F.Scanlan自2021年3月起担任我们的高级副总裁，营销和医学教育，在此之前，自2018年1月起担任我们的Vice President，营销和医学教育，自2014年12月起担任越来越重要的各种营销职务。在此之前，从2011年6月到2014年4月，Scanlan博士担任Smith&Nephew NYSE:SNN的高级外科设备产品开发工程师，专注于产品开发和早期技术评估。在此之前，Scanlan博士从2006年1月到2011年5月领导斯坦福大学（Stanford University）的跨学科临床研究研究，专注于骨科手术和工程，并从2009年10月到2011年5月担任Moximed Inc.的顾问，这是一家早期骨科初创公司。Scanlan先生拥有佛罗里达大学（University of Florida）工程科学（生物力学）学士学位和斯坦福大学（Stanford University）机械工程（生物力学工程系）硕士和博士学位。
- Sean F. Scanlan,has served as Treace Medical Concepts, Inc. Chief Innovation Officer since January 2023. From September 2021 until January 2023, he served as Treace Medical Concepts, Inc. Senior Vice President, Marketing, and from March 2021 to September 2021, he served as Treace Medical Concepts, Inc. Senior Vice President, Marketing & Medical Education. From January 2018 to March 2021, Dr. Scanlan served as Treace Medical Concepts, Inc. Vice President, Marketing & Medical Education, after serving in various marketing roles of increasing responsibility since December 2014. From June 2011 to April 2014, Dr. Scanlan served as Product Development Engineer Advanced Surgical Devices at Smith & Nephew (NYSE: SNN), focusing on product development and early-stage technology assessment. From January 2006 to May 2011, Dr. Scanlan led an interdisciplinary clinical research study at Stanford University, focusing on orthopaedic surgery and engineering and, from October 2009 to May 2011, served as a consultant for Moximed Inc., an early-stage orthopaedics start-up company. Dr. Scanlan holds a BS in Engineering Science (Biomechanics) from the University of Florida and an MS and PhD in Mechanical Engineering (Biomechanical Engineering division) from Stanford University.
- Scot M. Elder
Scot M. Elder，于2021年10月加入公司，担任首席合规官。2019年5月至2021年10月，Elder先生担任美敦力 PLC（NYSE：MDT）副总裁兼首席道德与合规官。他在美敦力 PLC工作了超过12年，担任的职务逐渐增加，包括担任副总裁、恢复性疗法集团的总法律顾问以及手术技术业务的副总裁、首席法律顾问、合规与隐私官。此外，他还在AdvaMed指导委员会任职。Elder先生拥有犹他大学历史学学士学位和加州大学洛杉矶分校（UCLA）法学院京东学位。
Scot M. Elder,joined the Company as Chief Compliance Officer in October 2021. From May 2019 until October 2021, Mr. Elder served as the Vice President and Chief Ethics and Compliance Officer of Medtronic plc (NYSE: MDT). He spent over 12 years at Medtronic plc in roles of progressively increasing responsibility, including as Vice President, General Counsel for the Restorative Therapies group and as Vice President, Chief Counsel, Compliance & Privacy Officer for the Surgical Technologies business. In addition, he serves on the AdvaMed Steering Committee. Mr. Elder holds a BA in History from the University of Utah and a JD from the University of California, Los Angeles (UCLA) Law School.- Scot M. Elder，于2021年10月加入公司，担任首席合规官。2019年5月至2021年10月，Elder先生担任美敦力 PLC（NYSE：MDT）副总裁兼首席道德与合规官。他在美敦力 PLC工作了超过12年，担任的职务逐渐增加，包括担任副总裁、恢复性疗法集团的总法律顾问以及手术技术业务的副总裁、首席法律顾问、合规与隐私官。此外，他还在AdvaMed指导委员会任职。Elder先生拥有犹他大学历史学学士学位和加州大学洛杉矶分校（UCLA）法学院京东学位。
- Scot M. Elder,joined the Company as Chief Compliance Officer in October 2021. From May 2019 until October 2021, Mr. Elder served as the Vice President and Chief Ethics and Compliance Officer of Medtronic plc (NYSE: MDT). He spent over 12 years at Medtronic plc in roles of progressively increasing responsibility, including as Vice President, General Counsel for the Restorative Therapies group and as Vice President, Chief Counsel, Compliance & Privacy Officer for the Surgical Technologies business. In addition, he serves on the AdvaMed Steering Committee. Mr. Elder holds a BA in History from the University of Utah and a JD from the University of California, Los Angeles (UCLA) Law School.
- Gaetano M. Guglielmino
Gaetano M. Guglielmino，于2023年1月至2024年12月期间在医疗技术公司Enovis Corporation（NYSE：ENOV）担任恢复科学总裁。在此之前，他曾于2021年3月至2023年1月在Enovis担任全球营销、支撑和支持副总裁，于2017年4月至2021年3月在赖特医疗集团 Inc.（于2020年11月被史赛克公司（NYSE：SYK）收购）担任全球营销和下肢医学教育副总裁，并于2012年至2021年3月在Bausch + Lomb担任一系列逐步更高级的营销职务，最终担任美国视力保健市场营销副总裁。Guglielmino先生在罗切斯特理工学院获得了商业与创业理学学士学位和MBA学位。
Gaetano M. Guglielmino,was President, Recovery Sciences at Enovis Corporation (NYSE: ENOV), a medical technology company, from January 2023 to December 2024. Before that, he held roles as Vice President Global Marketing, Bracing and Supports at Enovis from March 2021 to January 2023, Vice President of Global Marketing and Medical Education for Lower Extremities at Wright Medical Group Inc. (which was acquired by Stryker Corporation (NYSE: SYK) in November 2020) from April 2017 to March 2021, and held a series of progressively more senior marketing roles culminating as Vice President Marketing, US Vision Care, at Bausch + Lomb from 2012 to 2017. Mr. Guglielmino received his Bachelor of Science in Business & Entrepreneurship and his MBA from the Rochester Institute of Technology.- Gaetano M. Guglielmino，于2023年1月至2024年12月期间在医疗技术公司Enovis Corporation（NYSE：ENOV）担任恢复科学总裁。在此之前，他曾于2021年3月至2023年1月在Enovis担任全球营销、支撑和支持副总裁，于2017年4月至2021年3月在赖特医疗集团 Inc.（于2020年11月被史赛克公司（NYSE：SYK）收购）担任全球营销和下肢医学教育副总裁，并于2012年至2021年3月在Bausch + Lomb担任一系列逐步更高级的营销职务，最终担任美国视力保健市场营销副总裁。Guglielmino先生在罗切斯特理工学院获得了商业与创业理学学士学位和MBA学位。
- Gaetano M. Guglielmino,was President, Recovery Sciences at Enovis Corporation (NYSE: ENOV), a medical technology company, from January 2023 to December 2024. Before that, he held roles as Vice President Global Marketing, Bracing and Supports at Enovis from March 2021 to January 2023, Vice President of Global Marketing and Medical Education for Lower Extremities at Wright Medical Group Inc. (which was acquired by Stryker Corporation (NYSE: SYK) in November 2020) from April 2017 to March 2021, and held a series of progressively more senior marketing roles culminating as Vice President Marketing, US Vision Care, at Bausch + Lomb from 2012 to 2017. Mr. Guglielmino received his Bachelor of Science in Business & Entrepreneurship and his MBA from the Rochester Institute of Technology.
- Aaron J. Berutti
Aaron J. Berutti，曾在Orthofix Medical Inc.（NASDAQ：OFIX）担任过多个职位，最近担任Extremities-美国和加拿大销售与营销副总裁。2018年2月至2018年10月，Berutti先生在Cartiva，Inc.担任业务发展副总裁。2003年至2017年，Berutti先生在Wright Medical Group, Inc.担任多个职位，该公司于2020年11月被史赛克公司（纽约证券交易所代码：SYK）收购，最近一次是在2016年9月至2017年11月担任下肢与生物制剂销售副总裁。Berutti先生拥有范德比尔特大学机械工程学学士学位以及印第安纳大学凯利商学院的硕士和MBA学位。
Aaron J. Berutti,held various positions at Orthofix Medical Inc. (NASDAQ: OFIX), including most recently as the Vice President Sales & Marketing, Extremities-U.S. and Canada. From February 2018 to October 2018, Mr. Berutti served as the Vice President of Business Development at Cartiva, Inc. From 2003 to 2017, Mr. Berutti held various positions at Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, including most recently as the Vice President Sales, Lower Extremity & Biologics, from September 2016 to November 2017. Mr. Berutti holds a BE in Mechanical Engineering from Vanderbilt University and an MS and MBA from the Kelly School of Business at Indiana University.- Aaron J. Berutti，曾在Orthofix Medical Inc.（NASDAQ：OFIX）担任过多个职位，最近担任Extremities-美国和加拿大销售与营销副总裁。2018年2月至2018年10月，Berutti先生在Cartiva，Inc.担任业务发展副总裁。2003年至2017年，Berutti先生在Wright Medical Group, Inc.担任多个职位，该公司于2020年11月被史赛克公司（纽约证券交易所代码：SYK）收购，最近一次是在2016年9月至2017年11月担任下肢与生物制剂销售副总裁。Berutti先生拥有范德比尔特大学机械工程学学士学位以及印第安纳大学凯利商学院的硕士和MBA学位。
- Aaron J. Berutti,held various positions at Orthofix Medical Inc. (NASDAQ: OFIX), including most recently as the Vice President Sales & Marketing, Extremities-U.S. and Canada. From February 2018 to October 2018, Mr. Berutti served as the Vice President of Business Development at Cartiva, Inc. From 2003 to 2017, Mr. Berutti held various positions at Wright Medical Group, Inc., which was acquired by Stryker Corporation (NYSE: SYK) in November 2020, including most recently as the Vice President Sales, Lower Extremity & Biologics, from September 2016 to November 2017. Mr. Berutti holds a BE in Mechanical Engineering from Vanderbilt University and an MS and MBA from the Kelly School of Business at Indiana University.
- John T. Treace
John T. Treace，于2014年创立Treace Medical Concepts，并担任Treace Medical Concepts， Inc.的董事。Treace Medical Concepts, Inc.的首席执行官和成员。自Treace Medical Concepts， Inc.成立以来担任董事会成员。在此之前，Treace先生于2010年1月至2013年1月担任美国销售和全球营销高级副总裁，2003年1月至2009年12月担任生物制剂和四肢副总裁，2001年7月至2003年6月担任生物制剂营销高级总监，2000年11月至2001年6月担任Wright Medical Group， Inc.（一家医疗器械公司，于2020年11月被Stryker Corporation（纽约证券交易所股票：SYK）收购）的销售行政高级总监。在此之前，他曾担任Xomed Surgical Products， Inc.的职位，包括从1998年6月到2000年9月担任营销总监，从1996年4月到1998年6月担任高级产品经理。从2010年7月到2013年7月，Treace先生担任ENTrigue Surgical（被Arthrocare Corporation收购）的董事会成员。他持有Seattle大学的金融学士学位。
John T. Treace,founded Treace Medical Concepts in 2014 and has served as Treace Medical Concepts, Inc. Chief Executive Officer and a member of Treace Medical Concepts, Inc. Board since Treace Medical Concepts, Inc. inception. Before that, Mr. Treace served as Senior Vice President of U.S. Sales and Global Marketing from January 2010 to January 2013, as Vice President, Biologics and Extremities, from January 2003 to December 2009, as Senior Director of Biologics Marketing from July 2001 to June 2003, and as Senior Director of Sales Administration from November 2000 to June 2001 for Wright Medical Group, Inc., a medical device company, which was acquired by Stryker Corporation (NYSE: SYK) in November 2020. Before that, Mr. Treace held positions at Xomed Surgical Products, Inc., including as Director of Marketing from June 1998 to September 2000 and as Senior Product Manager from April 1996 to June 1998. From July 2010 to July 2013, Mr. Treace served on the board of directors of ENTrigue Surgical, which was acquired by Arthrocare Corporation. Mr. Treace holds a BS in Finance from Seattle University.- John T. Treace，于2014年创立Treace Medical Concepts，并担任Treace Medical Concepts， Inc.的董事。Treace Medical Concepts, Inc.的首席执行官和成员。自Treace Medical Concepts， Inc.成立以来担任董事会成员。在此之前，Treace先生于2010年1月至2013年1月担任美国销售和全球营销高级副总裁，2003年1月至2009年12月担任生物制剂和四肢副总裁，2001年7月至2003年6月担任生物制剂营销高级总监，2000年11月至2001年6月担任Wright Medical Group， Inc.（一家医疗器械公司，于2020年11月被Stryker Corporation（纽约证券交易所股票：SYK）收购）的销售行政高级总监。在此之前，他曾担任Xomed Surgical Products， Inc.的职位，包括从1998年6月到2000年9月担任营销总监，从1996年4月到1998年6月担任高级产品经理。从2010年7月到2013年7月，Treace先生担任ENTrigue Surgical（被Arthrocare Corporation收购）的董事会成员。他持有Seattle大学的金融学士学位。
- John T. Treace,founded Treace Medical Concepts in 2014 and has served as Treace Medical Concepts, Inc. Chief Executive Officer and a member of Treace Medical Concepts, Inc. Board since Treace Medical Concepts, Inc. inception. Before that, Mr. Treace served as Senior Vice President of U.S. Sales and Global Marketing from January 2010 to January 2013, as Vice President, Biologics and Extremities, from January 2003 to December 2009, as Senior Director of Biologics Marketing from July 2001 to June 2003, and as Senior Director of Sales Administration from November 2000 to June 2001 for Wright Medical Group, Inc., a medical device company, which was acquired by Stryker Corporation (NYSE: SYK) in November 2020. Before that, Mr. Treace held positions at Xomed Surgical Products, Inc., including as Director of Marketing from June 1998 to September 2000 and as Senior Product Manager from April 1996 to June 1998. From July 2010 to July 2013, Mr. Treace served on the board of directors of ENTrigue Surgical, which was acquired by Arthrocare Corporation. Mr. Treace holds a BS in Finance from Seattle University.